-$0.18 EPS Expected for Asterias Biotherapeutics Inc (NYSE:AST) This Quarter
Wall Street brokerages predict that Asterias Biotherapeutics Inc (NYSE:AST) will post earnings per share of ($0.18) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Asterias Biotherapeutics’ earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.18). Asterias Biotherapeutics reported earnings of ($0.16) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 12.5%. The firm is scheduled to report its next quarterly earnings results on Monday, August 21st.
On average, analysts expect that Asterias Biotherapeutics will report full year earnings of ($0.67) per share for the current fiscal year, with EPS estimates ranging from ($0.81) to ($0.58). For the next financial year, analysts forecast that the company will report earnings of ($0.67) per share, with EPS estimates ranging from ($0.72) to ($0.64). Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow Asterias Biotherapeutics.
Several equities research analysts have recently issued reports on AST shares. Zacks Investment Research downgraded shares of Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Asterias Biotherapeutics in a research report on Thursday, March 30th. Finally, Laidlaw began coverage on shares of Asterias Biotherapeutics in a research report on Tuesday, April 4th. They issued a “buy” rating and a $12.00 target price for the company.
Asterias Biotherapeutics (AST) traded up 0.735% during midday trading on Friday, hitting $3.425. 22,916 shares of the company traded hands. The firm’s market capitalization is $168.73 million. Asterias Biotherapeutics has a 12-month low of $2.54 and a 12-month high of $5.80. The stock’s 50-day moving average is $3.34 and its 200-day moving average is $3.68.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related stocks with our FREE daily email newsletter.